

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/076216 A1

(51) International Patent Classification⁷: **A01N 63/00**,
A61K 39/12, 39/245, C12N 7/00, 7/04

39 Mt. Vernon Street #1, Cambridge, MA 02140 (US).
RABKIN, Samuel, D. [CA/US]; 85 Dartmouth Street,
Lynn, MA 01904 (US). **TODO, Tomoki** [JP/US]; 16
Townsend Road, Belmont, MA 02478 (US).

(21) International Application Number: PCT/US02/09512

(22) International Filing Date: 27 March 2002 (27.03.2002)

(74) Agent: **MICHAUD, Susan, M.**; Clark & Elbing LLP, 101
Federal Street, Boston, MA 02110 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/279,069 27 March 2001 (27.03.2001) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/279,069 (CIP)
Filed on 27 March 2001 (27.03.2001)

(71) Applicants (for all designated States except US): **MEDI-
GENE, INC.** [US/US]; 9880 Campus Point Drive, Suite
A, San Diego, CA 92121 (US). **THE GENERAL HOSPI-
TAL CORPORATION** [US/US]; 55 Fruit Street, Boston,
MA 02114 (US). **GEORGETOWN UNIVERSITY**
[US/US]; 37th and O Street, NW, Washington, DC 20057
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHNSON, Paul**
[CA/CA]; 501-1250 Bute Street, Vancouver, British Co-
lumbia V6E 1Z9 (CA). **MARTUZA, Robert** [US/US];

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/076216 A1

(54) Title: VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

(57) Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

5

Field of the Invention

This invention relates to viruses and their use in therapeutic methods.

Background of the Invention

10 The use of replication-competent viral vectors, such as herpes simplex virus type 1 (HSV-1) vectors, is an attractive strategy for tumor therapy, because such viruses can replicate and spread *in situ*, exhibiting oncolytic activity through direct cytopathic effect (Kim, J. Clin. Invest. 105:837-839, 2000). A number of oncolytic HSV-1 vectors have been developed that have mutations in genes associated with neurovirulence and/or viral
15 DNA synthesis, in order to restrict replication of these vectors to transformed cells and not cause disease (Martuza, J. Clin. Invest. 105:841-846, 2000).

 In designing viral vectors for clinical use, it is essential that ample safeguards be employed. G207 is an oncolytic HSV-1 vector derived from wild-type HSV-1 strain F (Mineta et al., Nat. Med. 1:938-943, 1995). It has deletions in both copies of the major
20 determinant of HSV neurovirulence, the $\gamma 34.5$ gene, and an inactivating insertion of the *E. coli lacZ* gene in *UL39*, which encodes the infected-cell protein 6 (ICP6) (Mineta et al., Nat. Med. 1:938-943, 1995). ICP6 is the large subunit of ribonucleotide reductase, a key enzyme for nucleotide metabolism and viral DNA synthesis in non-dividing cells but not dividing cells (Goldstein et al., J. Virol. 62:196-205, 1988). In addition to being the
25 major determinant of HSV neurovirulence (Chou et al., Science 250:1262-1266, 1990), ICP34.5 also functions by blocking host cell induced shutoff of protein synthesis in response to viral infection (Chou et al., Proc. Natl. Acad. Sci. U.S.A. 89:3266-3270, 1992). This is likely responsible for the less efficient growth of $\gamma 34.5^-$ mutants compared to wild-type HSV, which has been observed in many tumor cell types (McKie
30 et al., Br. J. Cancer 74:745-752, 1996; Andreansky et al., Cancer Res. 57:1502-1509, 1997; Chambers et al., Proc. Natl. Acad. Sci. U.S.A. 92:1411-1415, 1995). This double mutation confers important advantages: minimal chance of reverting to wild type, preferential replication in tumor cells, attenuated neurovirulence, and

ganciclovir/acyclovir hypersensitivity. G207 effectively kills multiple types of tumor cells in culture and in mice harboring tumors subcutaneously or intracranially (Mineta et al., *Nat. Med.* 1:938-943, 1995; Yazaki et al., *Cancer Res.* 55:4752-4756, 1995; Toda et al., *Hum. Gene Ther.* 9:2177-2185, 1998; Todo et al., *Hum. Gene Ther.* 10:2741-2755, 1999; Chahlavi et al., *Neoplasia* 1:162-169, 1999; Kooby et al., *FASEB J.* 13:1325-1334, 1999; Lee et al., *J. Gastrointest. Surg.* 3:127-133, 1999). In several syngeneic tumor models in immunocompetent mice, oncolysis caused by intraneoplastic inoculation of G207 elicited a systemic immune response and tumor-specific cytotoxic T lymphocytes (Todo et al., *Hum. Gene Ther.* 10:2741-2755, 1999; Toda et al., *Hum. Gene Ther.* 10:385-393, 1999; Todo et al., *Hum. Gene Ther.* 10:2869-2878, 1999).

G207 has minimal toxicity when injected into the brains of HSV-1-susceptible mice or nonhuman primates (Hunter et al., *J. Virol.* 73:6319-6326, 1999; Sundaresan et al., *J. Virol.* 74:3832-3841, 2000; Todo et al., *Mol. Ther.* 2:588-595, 2000). Recently, G207 has been examined in patients with recurrent malignant glioma (Markert et al., *Gene Ther.* 7:867-874, 2000), and the results from this phase I clinical trial indicate that intracerebral inoculation of G207 is safe at doses of up to 3×10^9 plaque forming units (pfu), the highest dose tested. While the use of oncolytic viruses is a promising approach for cancer therapy, the therapeutic benefits will likely depend on the dose and route of administration, the extent of intratumoral viral replication, and the host immune response.

HSV-1 infection causes down-regulation of major histocompatibility complex (MHC) class I expression on the surface of infected host cells (Jennings et al., *J. Virol.* 56:757-766, 1985; Hill et al., *J. Immunol.* 152:2736-2741, 1994). The binding of ICP47 to the transporter associated with antigen presentation (TAP) blocks antigenic peptide transport in the endoplasmic reticulum and loading of MHC class I molecules (York et al., *Cell* 77:525-535, 1994; Hill et al., *Nature* 375:411-415, 1995; Fröh et al., *Nature* 375:415-418, 1995). The binding of ICP47 is species-specific for TAPs from large mammals (Jugovic et al., *J. Virol.* 72:5076-5084, 1998), with the affinity for murine TAP about 100-fold less than for human (Ahn et al., *EMBO J.* 15:3247-3255, 1996).

Summary of the Invention

The invention provides herpes simplex viruses (e.g., HSV-1 viruses) that include mutations within the BstEII - EcoNI fragment of the BamHI x fragment of the viruses. These viruses can also include, for example, an inactivating mutation in the $\gamma 34.5$ neurovirulence locus of the viruses, and/or an inactivating mutation in the ICP6 locus of the viruses.

Also included in the invention are herpes simplex viruses (e.g., an HSV-1 virus) that include an inactivating mutation in the ICP47 locus of the viruses, in the absence of an inactivating mutation in the $\gamma 34.5$ neurovirulence locuses of the virus. Optionally, these viruses also can include an inactivating mutation in the ICP6 locus of the viruses.

The invention also provides methods of inducing a systemic immune response to cancer in a patient, which involve administering to the patient a herpes virus that includes an inactivating mutation in the ICP47 locus of the herpes virus. The herpes virus can be administered, for example, to a tumor of the patient. In addition, the patient can have or be at risk of developing metastatic cancer, and the treatment can be carried out to treat or prevent such cancer. The inactivating mutation in the ICP47 locus of the herpes virus can be, for example, in the BstEII - EcoNI fragment of the BamHI x fragment of the virus. Optionally, the virus can include an inactivating mutation in the $\gamma 34.5$ neurovirulence locus of the herpes virus, and/or an inactivating mutation in the ICP6 locus of the herpes virus.

The invention also provides herpes viruses that include a first mutation that inactivates the $\gamma 34.5$ neurovirulence locus of the viruses and a second mutation that results in early expression of US11, in the absence of an ICP47-inactivating mutation in the BamHI x fragment of the viruses. Early expression of US11 can be achieved, for example, by inserting a promoter upstream from the US11 gene, or by inserting a US11 gene under the control of an early-expressing promoter into the genome of the virus. The viruses can also include a mutation that results in downregulation of ICP47 expression, in the absence of a mutation in the BamHI x fragment of the virus. The downregulation of ICP47 can be due to, for example, a deletion in, or inactivation of, the ICP47 promoter, or the fusion of ICP47 with a peptide that prevents functional expression of ICP47.

The invention also includes a herpes virus that includes a first mutation that inactivates the γ 34.5 neurovirulence locus of the virus and a second mutation that results in downregulation of ICP47 expression, in the absence of a mutation in the BamHI x fragment of the virus. The downregulation of ICP47 can be due to, for example, a deletion in, or inactivation of, the ICP47 promoter, or the fusion of ICP47 with a peptide that prevents functional expression of ICP47.

The viruses described above can also include an additional mutation (e.g., a mutation in the ICP6 locus) to prevent reversion to wild type. The viruses can also include, optionally, sequences encoding a heterologous gene product, such as a vaccine antigen or an immunomodulatory protein. The viruses described herein can be herpes simplex viruses (HSV), such as herpes simplex-1 viruses (HSV-1).

The invention further provides pharmaceutical compositions that include any of the viruses described herein and a pharmaceutically acceptable carrier, adjuvant, or diluent, as well as methods of treating cancer in a patient, involving administering such a pharmaceutical composition to the patient. Also included in the invention are methods of immunizing a patient against an infectious disease, cancer, or an autoimmune disease, involving administering such a pharmaceutical composition to the patient.

The invention provides several advantages. For example, the viruses of the invention replicate in, and thus destroy, dividing cells, such as cancer cells, while not affecting other cells in the body. An additional advantage of the viruses of the invention in which ICP47 is deleted is that the immune response induced by such viruses is enhanced, which results in a better antitumor immune response. The viruses of the invention also include multiple mutations, eliminating the possibility of reversion to wild type. Moreover, although the viruses of the invention may have enhanced replication, this is not accompanied by increased toxicity. In addition, replication of herpes simplex viruses can be controlled through the action of antiviral drugs, such as acyclovir, which block viral replication. These features render the viruses of the invention to be not only effective, but safe as well.

Other features and advantages of the invention will be apparent from the following detailed description, drawings, and claims.

Brief Description of the Drawings

Figs. 1A-1E are schematic representations of the HSV-1 genome and approaches to making vectors included in the invention. Fig. 1A is a schematic representation of the HSV-1 genome. Fig. 1B is an expanded map of the ICP47 locus, showing the locations of the overlapping 3' co-terminal transcripts for US10, US11, and US12 (ICP47). Fig. 1C is a schematic representation of plasmid pIE12, which contains an 1818 basepair BamHI-EcoRI fragment from the HSV-1 BamHI x fragment, which encompasses the ICP47 region (Johnson et al., J. Virology 68(10):6347-6362, 1994). This plasmid can be used to introduce modifications into the ICP47 locus of the viral genome, as is described further below. Fig. 1D is a schematic representation of plasmid pIE12 Δ , which was derived from pIE12 by deleting 312 basepairs between the indicated BstEII and NruI sites. This plasmid was used to generate the γ 34.5 suppressor mutants R47 Δ and G47 Δ . Fig. 1E is a schematic representation of the details of the 3' terminus of the ICP47 coding region. Sequences can be inserted into the indicated BstEII site, without disrupting sequences between the BstEII and NruI sites, for the purposes of changing the temporal regulation of the late US11 gene, to generate a γ 34.5 suppressor function, and/or preventing functional expression of the ICP47 gene product.

Figs. 2A-2C are schematic representations of the structure of G47 Δ . Fig. 2A is a schematic of the HSV-1 genome showing the regions modified in G47 Δ . The HSV-1 genome consists of long and short unique regions (U_L and U_S), each bounded by terminal (T) and internal (I) repeat regions (R_L and R_S). The parental virus G207 was engineered from wild-type HSV-1 strain F by deleting 1 kilobase within both copies of the γ 34.5 gene, and inserting the *E. coli lacZ* gene into the ICP6 coding region. G47 Δ was derived from G207 by deleting 312 basepairs from the ICP47 locus, as indicated. Fig. 2B is a map of the ICP47 locus, showing locations of the overlapping 3' co-terminal transcripts (US10, US11, and ICP47), open reading frames (thick arrow), and ICP47 splice junctions (^). Fig. 2C is a map of plasmid pIE12 Δ , which was used to generate deletions by homologous recombination with the indicated flanking sequences. While US11 is regulated as a true late gene in wild-type HSV-1, deletion between the indicated BstEII and EcoNI sites places US11 under control of the ICP47 immediate-early promoter. Restriction site abbreviations are: B, BamHI; Bs, BstEII; E, EcoRI; EN, EcoNI; Nr, NruI.

Fig. 3 is a graph showing virus yields of replication-competent HSV-1 mutants in various cell lines. Cells were seeded on 6 well plates at 5×10^5 cells/well. Triplicate wells were infected with R3616, R47 Δ , G207, G47 Δ , or strain F at a MOI of 0.01. At 24 hours post-infection, cells were scraped into the medium and progeny virus was titered on Vero cells. In all cell lines tested, G47 Δ showed a significantly higher replication capability than G207. Results represent the mean of triplicates \pm SD.

Fig. 4 is a series of graphs showing the cytopathic effect of G47 Δ *in vitro*. Cells were plated into 6 well plates at 2×10^5 cells/well. After 24 hours of incubation, cells were infected with G207 or G47 Δ at a MOI of 0.01 or 0.1, or without virus (Control). The number of surviving cells was counted daily and expressed as a percentage of mock-infected controls. G47 Δ exhibited a significantly stronger cytopathic effect than G207 in all three human tumor cell lines (U87MG and melanomas 624 and 888) at a MOI of 0.01, and also in Neuro2a murine neuroblastoma cells at a MOI of 0.1. The results are the mean of triplicates \pm SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, G207 versus G47 Δ , unpaired t test.

Figs. 5A-5C are a series of graphs showing that G47 Δ precludes down-regulation of MHC class I expression in infected host cells. Fig. 5A is a graph of flow cytometric analyses of MHC class I expression in Detroit 551 human fibroblast cells 48 hours after infection with HSV-1 (MOI = 3). While all HSVs with an intact $\alpha 47$ gene (wild-type strain F and G207) significantly down-regulated MHC class I expression, G47 Δ completely precluded the down-regulation. Fig. 5B is a graph showing a time course of MHC class I down-regulation in Detroit 551 cells infected with HSV-1. For each virus, the peak value of MHC class I expression at 6, 24, or 48 hours post-infection, analyzed by flow cytometry, was expressed as a percentage of the peak value of mock-infected cells (control) at each time point. MHC class I down-regulation by G207 and R3616 occurred in a time-dependent fashion. Dissociation of MHC class I expression between $\alpha 47$ -deleted mutants (G47 Δ and R47 Δ) and $\alpha 47$ -intact viruses became apparent at 24-48 hours post-infection. Fig. 5C is a series of graphs showing flow cytometric analyses of MHC class I expression in human melanoma cell lines 24 hours after infection with G207 and G47 Δ . G47 Δ caused a partial preclusion of MHC class I down-regulation in melanomas 1102 and 938, resulting in greater MHC class I expression than G207.

Fig. 6 is a series of graphs showing that G47 Δ -infected tumor cells stimulate T cells to a greater extent than G207-infected tumor cells. Human melanoma cells were infected with mock (no virus), G207, or G47 Δ at a MOI of 3, and after 3-6 hours, co-cultured with an equal number of responding human T cells for 18 hours. T cell stimulation was assessed by an increase in IFN- γ release into conditioned media. G47 Δ -infected melanoma 1102 cells caused a significantly greater stimulation of TIL888 cells compared with G207-infected 1102 cells ($p < 0.01$, unpaired t test). G47 Δ -infected 938 melanoma cells also stimulated TIL1413 cells, although the improvement was not statistically significant compared with G207-infected 938 cells ($p = 0.1$, unpaired t test). Neither G207 nor G47 Δ -infected melanoma 888 cells caused a significant stimulation of TIL888 cells.

Fig. 7 is a set of graphs showing that G47 Δ exhibits greater antitumor efficacy than G207 *in vivo*. Subcutaneous tumors of U87MG human glioma (Left) or Neuro2a murine neuroblastoma (Right) were generated in 6-week-old female athymic mice or 6-week-old female A/J mice, respectively. Established tumors of approximately 6 mm in diameter were inoculated with G207 or G47 Δ (1×10^6 pfu), or mock (PBS with 10% glycerol) on days 0 and 3. G47 Δ treatment was significantly more efficacious than G207 in both tumor models, resulting in smaller average tumor volumes ($p < 0.05$ for U87MG on day 24 and $p < 0.001$ for Neuro2a on day 15, G207 versus G47 Δ , unpaired t test).

Detailed Description

The invention provides viruses that can be used in therapeutic methods, such as, for example, in the treatment of cancer. These viruses are particularly well suited for this purpose, as they replicate in, and thus destroy, dividing cells (e.g., cancer cells), but they do not replicate substantially, and thus are avirulent, in non-dividing cells. The viruses of the invention can also be used in immunization methods, for the treatment or prevention of, for example, infectious diseases, cancer, or autoimmune diseases. An advantageous feature of many of the viruses of the invention is that, in addition to directly causing lysis of tumor cells, they induce a systemic immune response against tumors. Thus, these viruses can be used not only to treat a given tumor, to which they may be directly administered, but also to prevent or treat cancer metastasis.

Several of the viruses of the invention are herpes simplex viruses (HSV) that include an inactivating mutation in the ICP47 locus of the virus. This mutation can

occur, for example, between the BstEII site and the EcoNI site of the BamHI x fragment of HSV-1, and may comprise, e.g., deletion of the BstEII - ExoNI fragment. Optionally, a herpes simplex virus including a mutation between the BstEII and EcoNI sites can also include additional mutations. For example, such a virus can include an inactivating
5 mutation in the γ 34.5 neurovirulence determination locus of the virus, and/or an inactivating mutation elsewhere in the genome, e.g., in the ICP6 locus. The invention also includes herpes simplex viruses that include inactivating mutations in the ICP47 locus, in the absence of an inactivating mutation in the γ 34.5 neurovirulence locus. Optionally, such a virus can include an inactivating mutation in another, non- γ 34.5
10 neurovirulence locus, e.g., in the ICP6 locus.

The invention includes additional viruses that are based on herpes viruses, such as herpes simplex (HSV viruses), for example, HSV-1 (e.g., HSV-1 strain F or strain Patton) or HSV-2, that include an inactivating mutation in a virulence gene. In the case of herpes simplex viruses, this mutation can be an inactivating mutation in the γ 34.5
15 gene, which is the major HSV neurovirulence determinant. (See, e.g., Fig. 1 for details concerning the construction of examples of viruses that are included in the invention.)

In addition to the γ 34.5 mutation, in one example, the viruses of the invention can include a modification that results in early expression of US11, in the absence of an ICP-47-inactivating mutation in the BamHI x fragment of the vector. US11 is normally
20 expressed as a true-late gene, requiring DNA replication for its expression. However, early expression of US11 in some of the viruses of the invention can compensate for the γ 34.5 defect by preventing the PKR-mediated shut-off of protein synthesis (see, e.g., Fig. 1E). Early expression of US11 in such a virus can be achieved by, for example, inserting an early-acting promoter upstream of the US11 gene (Fig. 1E). Such promoters can
25 include, for example, the human cytomegalovirus (CMV) IE promoter, an HSV-1 IE promoter, an HSV-1 E promoter, or any other heterologous promoter that is active before the onset of DNA replication in the HSV-1 genome (see, e.g., below). An alternative approach to achieving early expression of US11 included in the invention involves inserting an exogenous copy of a US11 gene elsewhere in the viral genome, under the
30 control of any suitable promoter that is active early in infection, such as one of those listed above, for example.

An additional HSV-based virus included in the invention includes, in addition to an inactivating mutation in the γ 34.5 locus, a second modification that results in

downregulation of ICP47 expression, in the absence of a mutation in the BamHI x fragment of the virus. In one example of such a virus, ICP47 coding sequences are fused with sequences that encode a peptide that prevents functional expression of ICP47 (see, e.g., Fig. 1E). Such a peptide can include, for example, a PEST sequence, which is rich in proline (P), glutamate (E), serine (S), and threonine (T), and thus provides intramolecular signals for rapid proteolytic degradation (Rechsteiner et al., Trends Biochem. Sci. 21(7):267-271, 1996). Such a poison sequence can be inserted into the virus at, for example, the BstEII site, upstream of a strong promoter driving US11 (Fig. 1E). In an alternative vector, signals that direct RNA degradation are incorporated into the virus, to direct degradation of ICP47 RNA.

Other viruses included in the invention can include, in addition to an inactivating mutation in the γ 34.5 locus, two additional modifications. The first additional modification results in early expression of US11 and the second modification results in downregulation of ICP47 expression, as described above, in the absence of a mutation in the BamHI x fragment of the virus. In one example of such a virus, an early-expressing promoter is inserted upstream of the US11 gene and ICP47 coding sequences are fused with sequences encoding a poison sequence, such as a PEST sequence (Fig. 1E).

Any of the viruses described above and herein and elsewhere can include an additional mutation or modification that is made to prevent reversion of the virus to wild type. For example, the virus can include a mutation in the ICP6 gene (see below), which encodes the large subunit of ribonucleotide reductase. A specific example of a virus that is included in the invention, G47 Δ , is described in further detail below. Briefly, this virus includes a deletion in the γ 34.5 gene, an inactivating insertion in the ICP6 gene, and a 312 basepair deletion in the ICP47 gene.

The viruses described herein can be generated from any herpes virus family member, such as a neurotrophic, B-lymphotrophic, or T-lymphotrophic herpes virus. For example, a herpes simplex virus (HSV), such as HSV-1 or HSV-2, can be used. Alternatively, any of the following viruses can be used: Varicella-zoster virus (VZV), herpes virus 6 (HSV-6), Epstein Barr virus, cytomegalovirus, HHV6, and HHV7. The methods and viruses described herein are described primarily in reference to HSV-1, but these methods can readily be applied to any of these other viruses by one of skill in this art.

As is noted above, the viruses of the invention can be used to treat cancer, as these viruses replicate in, and thus destroy dividing cells, such as cancer cells, but are avirulent to other cells. Examples of cancer cells that can be destroyed, according to the invention, include cancer cells of nervous-system type tumors, for example, astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, neuroblastoma, pituitary tumor (e.g., pituitary adenoma), and medulloblastoma cells. Other types of tumor cells that can be killed, pursuant to the present invention, include, for example, melanoma, prostate carcinoma, renal cell carcinoma, pancreatic cancer, breast cancer, lung cancer, colon cancer, gastric cancer, fibrosarcoma, squamous cell carcinoma, neurectodermal, thyroid tumor, lymphoma, hepatoma, mesothelioma, and epidermoid carcinoma cells, as well as other cancer cells mentioned herein. Also as is noted above, the viruses of the invention, which induce a systemic immune response to cancer, can be used to prevent or to treat cancer metastasis.

Other therapeutic applications in which killing of a target cell is desirable include, for example, ablation of keratinocytes and epithelial cells responsible for warts, ablation of cells in hyperactive organs (e.g., thyroid), ablation of fat cells in obese patients, ablation of benign tumors (e.g., benign tumors of the thyroid or benign prostatic hypertrophy), ablation of growth hormone-producing adenohypophyseal cells to treat acromegaly, ablation of mamatotropes to stop the production of prolactin, ablation of ACTH-producing cells to treat Cushing's disease, ablation of epinephrine-producing chromaffin cells of the adrenal medulla to treat pheochromocytoma, and ablation of insulin-producing beta islet cells to treat insulinoma. The viruses of the invention can be used in these applications as well.

The effects of the viruses of the invention can be augmented if the viruses also contain a heterologous nucleic acid sequence encoding one or more therapeutic products, for example, a cytotoxin, an immunomodulatory protein (i.e., a protein that either enhances or suppresses a host immune response to an antigen), a tumor antigen, an antisense RNA molecule, or a ribozyme. Examples of immunomodulatory proteins include, e.g., cytokines (e.g., interleukins, for example, any of interleukins 1-15, α , β , or γ -interferons, tumor necrosis factor, granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and granulocyte colony stimulating factor (G-CSF)), chemokines (e.g., neutrophil activating protein (NAP),

macrophage chemoattractant and activating factor (MCAF), RANTES, and macrophage inflammatory peptides MIP-1a and MIP-1b), complement components and their receptors, immune system accessory molecules (e.g., B7.1 and B7.2), adhesion molecules (e.g., ICAM-1, 2, and 3), and adhesion receptor molecules. Examples of tumor antigens that can be produced using the present methods include, e.g., the E6 and E7 antigens of human papillomavirus, EBV-derived proteins (Van der Bruggen et al., Science 254:1643-1647, 1991), mucins (Livingston et al., Curr. Opin. Immun. 4(5):624-629, 1992), such as MUC1 (Burchell et al., Int. J. Cancer 44:691-696, 1989), melanoma tyrosinase, and MZ2-E (Van der Bruggen et al., supra). (Also see WO 94/16716 for a further description of modification of viruses to include genes encoding tumor antigens or cytokines.)

As is noted above, the therapeutic product can also be an RNA molecule, such as an antisense RNA molecule that, by hybridization interactions, can be used to block expression of a cellular or pathogen mRNA. Alternatively, the RNA molecule can be a ribozyme (e.g., a hammerhead or a hairpin-based ribozyme) designed either to repair a defective cellular RNA, or to destroy an undesired cellular or pathogen-encoded RNA (see, e.g., Sullenger, Chem. Biol. 2(5):249-253, 1995; Czubayko et al., Gene Ther. 4(9):943-949, 1997; Rossi, Ciba Found. Symp. 209:195-204, 1997; James et al., Blood 91(2):371-382, 1998; Sullenger, Cytokines Mol. Ther. 2(3):201-205, 1996; Hampel, Prog. Nucleic Acid Res. Mol. Bio. 58:1-39, 1998; Curcio et al., Pharmacol. Ther. 74(3):317-332, 1997).

A heterologous nucleic acid sequence can be inserted into a virus of the invention in a location that renders it under the control of a regulatory sequence of the virus. Alternatively, the heterologous nucleic acid sequence can be inserted as part of an expression cassette that includes regulatory elements, such as promoters or enhancers. Appropriate regulatory elements can be selected by those of ordinary skill in the art based on, for example, the desired tissue-specificity and level of expression. For example, a cell-type specific or tumor-specific promoter can be used to limit expression of a gene product to a specific cell type. This is particularly useful, for example, when a cytotoxic, immunomodulatory, or tumor antigenic gene product is being produced in a tumor cell in order to facilitate its destruction. In addition to using tissue-specific promoters, local administration of the viruses of the invention can result in localized expression and effect.

Examples of non-tissue specific promoters that can be used in the invention include the early Cytomegalovirus (CMV) promoter (U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter (Norton et al., *Molec. Cell. Biol.* 5:281, 1985). Also, HSV promoters, such as HSV-1 IE and IE 4/5 promoters, can be used.

- 5 Examples of tissue-specific promoters that can be used in the invention include, for example, the prostate-specific antigen (PSA) promoter, which is specific for cells of the prostate; the desmin promoter, which is specific for muscle cells (Li et al., *Gene* 78:243, 1989; Li et al., *J. Biol. Chem.* 266:6562, 1991; Li et al., *J. Biol. Chem.* 268:10403, 1993); the enolase promoter, which is specific for neurons (Forss-Petter et al., *J. Neuroscience Res.* 16(1):141-156, 1986); the β -globin promoter, which is specific for erythroid cells (Townes et al., *EMBO J.* 4:1715, 1985); the tau-globin promoter, which is also specific for erythroid cells (Brinster et al., *Nature* 283:499, 1980); the growth hormone promoter, which is specific for pituitary cells (Behringer et al., *Genes Dev.* 2:453, 1988); the insulin promoter, which is specific for pancreatic β cells (Selden et al., *Nature* 321:545, 1986); the glial fibrillary acidic protein promoter, which is specific for astrocytes (Brenner et al., *J. Neurosci.* 14:1030, 1994); the tyrosine hydroxylase promoter, which is specific for catecholaminergic neurons (Kim et al., *J. Biol. Chem.* 268:15689, 1993); the amyloid precursor protein promoter, which is specific for neurons (Salbaum et al., *EMBO J.* 7:2807, 1988); the dopamine β -hydroxylase promoter, which is specific for noradrenergic and adrenergic neurons (Hoyle et al., *J. Neurosci.* 14:2455, 1994); the tryptophan hydroxylase promoter, which is specific for serotonin/pineal gland cells (Boularand et al., *J. Biol. Chem.* 270:3757, 1995); the choline acetyltransferase promoter, which is specific for cholinergic neurons (Hersh et al., *J. Neurochem.* 61:306, 1993); the aromatic L-amino acid decarboxylase (AADC) promoter, which is specific for catecholaminergic/5-HT/D-type cells (Thai et al., *Mol. Brain Res.* 17:227, 1993); the proenkephalin promoter, which is specific for neuronal/spermatogenic epididymal cells (Borsook et al., *Mol. Endocrinol.* 6:1502, 1992); the reg (pancreatic stone protein) promoter, which is specific for colon and rectal tumors, and pancreas and kidney cells (Watanabe et al., *J. Biol. Chem.* 265:7432, 1990); and the parathyroid hormone-related peptide (PTHrP) promoter, which is specific for liver and cecum tumors, and neurilemoma, kidney, pancreas, and adrenal cells (Campos et al., *Mol. Endocrinol.* 6:1642, 1992).

Examples of promoters that function specifically in tumor cells include the stromelysin 3 promoter, which is specific for breast cancer cells (Basset et al., Nature 348:699, 1990); the surfactant protein A promoter, which is specific for non-small cell lung cancer cells (Smith et al., Hum. Gene Ther. 5:29-35, 1994); the secretory leukoprotease inhibitor (SLPI) promoter, which is specific for SLPI-expressing carcinomas (Garver et al., Gene Ther. 1:46-50, 1994); the tyrosinase promoter, which is specific for melanoma cells (Vile et al., Gene Therapy 1:307, 1994; WO 94/16557; WO 93/GB1730); the stress inducible grp78/BiP promoter, which is specific for fibrosarcoma/tumorigenic cells (Gazit et al., Cancer Res. 55(8):1660, 1995); the AP2 adipose enhancer, which is specific for adipocytes (Graves, J. Cell. Biochem. 49:219, 1992); the α -1 antitrypsin transthyretin promoter, which is specific for hepatocytes (Grayson et al., Science 239:786, 1988); the interleukin-10 promoter, which is specific for glioblastoma multiform cells (Nitta et al., Brain Res. 649:122, 1994); the c-erbB-2 promoter, which is specific for pancreatic, breast, gastric, ovarian, and non-small cell lung cells (Harris et al., Gene Ther. 1:170, 1994); the α -B-crystallin/heat shock protein 27 promoter, which is specific for brain tumor cells (Aoyama et al., Int. J. Cancer 55:760, 1993); the basic fibroblast growth factor promoter, which is specific for glioma and meningioma cells (Shibata et al., Growth Fact. 4:277, 1991); the epidermal growth factor receptor promoter, which is specific for squamous cell carcinoma, glioma, and breast tumor cells (Ishii et al., Proc. Natl. Acad. Sci. U.S.A. 90:282, 1993); the mucin-like glycoprotein (DF3, MUC1) promoter, which is specific for breast carcinoma cells (Abe et al., Proc. Natl. Acad. Sci. U.S.A. 90:282, 1993); the mts1 promoter, which is specific for metastatic tumors (Tulchinsky et al., Proc. Natl. Acad. Sci. U.S.A. 89:9146, 1992); the NSE promoter, which is specific for small-cell lung cancer cells (Forss-Petter et al., Neuron 5:187, 1990); the somatostatin receptor promoter, which is specific for small cell lung cancer cells (Bombardieri et al., Eur. J. Cancer 31A:184, 1995; Koh et al., Int. J. Cancer 60:843, 1995); the c-erbB-3 and c-erbB-2 promoters, which are specific for breast cancer cells (Quin et al., Histopathology 25:247, 1994); the c-erbB4 promoter, which is specific for breast and gastric cancer cells (Rajkumar et al., Breast Cancer Res. Trends 29:3, 1994); the thyroglobulin promoter, which is specific for thyroid carcinoma cells (Mariotti et al., J. Clin. Endocrinol. Meth. 80:468, 1995); the α -fetoprotein promoter, which is specific for hepatoma cells (Zuibel et al., J. Cell. Phys. 162:36, 1995); the villin promoter, which is specific for gastric cancer cells (Osborn et

al., Virchows Arch. A. Pathol. Anat. Histopathol. 413:303, 1988); and the albumin promoter, which is specific for hepatoma cells (Huber, Proc. Natl. Acad. Sci. U.S.A. 88:8099, 1991).

As is noted above, the viruses of the invention can be used in *in vivo* methods, for example, to kill a cell and/or to introduce a therapeutic gene product into the cell. To carry out these methods, the viruses of the invention can be administered by any conventional route used in medicine. For example, a virus of the invention can be administered directly into a tissue in which an effect, e.g., cell killing and/or therapeutic gene expression, is desired, for example, by direct injection or by surgical methods (e.g., stereotactic injection into a brain tumor; Pellegrino et al., Methods in Psychobiology (Academic Press, New York, New York, 67-90, 1971)). An additional method that can be used to administer vectors into the brain is the convection method described by Bobo et al. (Proc. Natl. Acad. Sci. U.S.A. 91:2076-2080, 1994) and Morrison et al. (Am. J. Physiol. 266:292-305, 1994). In the case of tumor treatment, as an alternative to direct tumor injection, surgery can be carried out to remove the tumor, and the vectors of the invention inoculated into the resected tumor bed to ensure destruction of any remaining tumor cells. Alternatively, the vectors can be administered via a parenteral route, e.g., by an intravenous, intraarterial, intracerebroventricular, subcutaneous, intraperitoneal, intradermal, intraepidermal, or intramuscular route, or via a mucosal surface, e.g., an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, or urinary tract surface.

Any of a number of well-known formulations for introducing viruses into cells in mammals, such as humans, can be used in the invention. (See, e.g., Remington's Pharmaceutical Sciences (18th edition), ed. A. Gennaro, 1990, Mack Publishing Co., Easton, PA.) However, the viruses can be simply diluted in a physiologically acceptable solution, such as sterile saline or sterile buffered saline, with or without an adjuvant or carrier.

The amount of virus to be administered depends, e.g., on the specific goal to be achieved, the strength of any promoter used in the virus, the condition of the mammal (e.g., human) intended for administration (e.g., the weight, age, and general health of the mammal), the mode of administration, and the type of formulation. In general, a therapeutically or prophylactically effective dose of, e.g., from about 10^1 to 10^{10} plaque forming units (pfu), for example, from about 5×10^4 to 1×10^6 pfu, e.g., from about 1×10^5 to about 4×10^5 pfu, although the most effective ranges may vary from host to host, as can

readily be determined by one of skill in this art. Also, the administration can be achieved in a single dose or repeated at intervals, as determined to be appropriate by those of skill in this art.

5 A specific example of a virus of the invention, designated G47 Δ , which is a new, multimutated, replication-competent HSV-1 virus, derived from G207 by a deletion within the non-essential $\alpha 47$ gene (Mavromara-Nazos et al., J. Virol. 60:807-812, 1986), is now described. Because of the overlapping transcripts encoding ICP47 and US11 (Fig. 2B), the deletion in $\alpha 47$ also places the late *US11* gene under control of the immediate-early $\alpha 47$ promoter. This enhances the growth properties of $\gamma 34.5^-$ mutants
10 by precluding the shutoff of protein synthesis (Mohr et al., EMBO J. 15:4759-4766, 1996; He et al., J. Virol. 71:6049-6054, 1997; Cassady et al., J. Virol. 72:7005-7011, 1998; Cassady et al., J. Virol. 72:8620-8626, 1998). Nevertheless, we found that G47 Δ was as safe as G207, which is now in clinical trials in humans, when inoculated into the brains of A/J mice at 2×10^6 pfu. We show here that human melanoma cells infected
15 with G47 Δ were more effective at stimulating their matched tumor-infiltrating lymphocytes (TILs) than those infected with G207, that G47 Δ showed enhanced replication in cultured tumor cells, and that G47 Δ was more efficacious than G207 at inhibiting tumor growth in both human xenograft and mouse syngeneic tumor models tested. Our results show that G47 Δ can be used for tumor therapy. Additional details of
20 this virus and its properties are provided as follows.

Experimental Results

Construction and Replication of G47 Δ

25 G47 Δ was constructed by deleting 312 basepairs from G207 in the *U_S* region adjacent to TR_S (Fig. 2). Southern blot analyses of G47 Δ DNA confirmed the presence of a 0.3 kilobase deletion in the $\alpha 47$ gene and a 1 kilobase deletion in the $\gamma 34.5$ gene. R47 Δ , with the same deletion in the $\alpha 47$ locus, was generated from R3616, the parental virus of G207 that has an active ribonucleotide reductase (Chou et al., Science 250:1262-1266, 1990).

30 To investigate the effects of the $\alpha 47$ deletion on the growth properties of $\gamma 34.5^-$ deficient mutants (G207 and R3616), we determined the yield of progeny virus following infection of human tumor cells lines SK-N-SH (neuroblastoma), U87MG

(glioma), U373MG (glioma), and SQ20B (head and neck squamous cell carcinoma). By 24 hours post-infection at a low MOI, G47 Δ produced higher yields than G207, resulting in an approximately 4 to 1000-fold increase in titer (Fig. 3). In a single-step growth experiment in U87MG cells (MOI=2), the virus yield of G47 Δ was 12 times greater than with G207. R47 Δ similarly yielded higher titers than its parent R3616 in all tumor cell lines tested; however, neither G47 Δ nor R47 Δ grew as well as wild-type parental strain F. To determine whether virus yields were affected by cell density, Vero and SK-H-SH cells were seeded at normal or high density (8×10^5 or 1.6×10^6 cells/well), infected with strain F, G207, or G47 Δ at a MOI of 0.01, and harvested 48 hours post-infection. G47 Δ produced a higher yield in the high-density culture, as opposed to G207, which had a reduced yield. The ability to generate higher yields of G47 Δ in Vero cells facilitates manufacturing of high titer stocks for clinical use.

Cytopathic Effect of G47 Δ *In Vitro*

The cytolytic activity of G47 Δ *in vitro* was compared to that of G207 in various neural crest-derived tumor cell lines. In human cell lines, U87MG and melanomas 624 and 888, G47 Δ killed tumor cells significantly more rapidly than G207 at a low MOI of 0.01 (Fig. 4). At a MOI of 0.1, both G207 and G47 Δ killed all the cells within 1-3 days of infection. Neuro2a, a murine neuroblastoma cell line, was resistant to killing by both G207 and G47 Δ at a MOI of 0.01. At a MOI of 0.1, G47 Δ was significantly more efficient at destroying tumor cells than G207 (Fig. 4), an effect also seen with N18 mouse neuroblastoma cells. We have found that mouse tumor cells are generally more resistant to G207 replication than human tumor cells (Todo et al., Hum. Gene Ther. 10:2741-2755, 1999; Toda et al., Hum. Gene Ther. 10:385-393, 1999; Todo et al., Cancer Res. 61:153-161, 2001).

MHC Class I Expression in G47 Δ -Infected Cells

ICP47 inhibits the function of TAP in translocating peptides across the endoplasmic reticulum in human cells, but not in mouse or rat cells (Ahn et al., EMBO J. 15:3247-3255, 1996; Tomazin et al., J. Virol. 72:2560-2563, 1998). Because G47 Δ lacks ICP47, infected cells should have levels of MHC class I expression typical of uninfected cells. We examined MHC class I down-regulation in Detroit 551 human diploid fibroblasts using flow cytometric analyses for human lymphocyte antigen class I

(HLA-1). At 48 hours post-infection, all cells infected with HSV-1 containing an intact $\alpha 47$ gene (strain F, G207, and R3616) showed a decrease in cell surface MHC class I, resulting in approximately 40% in peak levels compared to mock-infected control cells (Figs. 5A and 5B). By contrast, there was no down-regulation in G47 Δ infected cells (Fig. 5A). In R47 Δ -infected cells, MHC class I expression remained higher than in strain F or R3616-infected cells, but was reduced compared to G47 Δ (~75% of mock-infected peak levels). Studies at different time points (6, 24, and 48 hours post-infection) revealed that differences in MHC class I down-regulation between ICP47 expressing (G207 and R3616) and non-expressing (G47 Δ and R47 Δ) infected cells did not become apparent until after 6 hours post-infection (Fig. 5B).

Infection of human melanoma cells with G47 Δ also resulted in higher levels of MHC class I expression than with G207, although the preclusion of down-regulation was partial. In general, a greater effect was observed in cell lines with high basal levels of MHC class I (938 and 1102) compared to those with low levels of MHC class I (624, 888, and 1383) (Fig. 5C).

G47 Δ -Infected Human Melanoma Cells Stimulate Human T Cells *In Vitro*

Three human melanoma cell lines were tested for their abilities to stimulate the matched TIL lines after G47 Δ infection (888 and 1102 with TIL888 (Robbins et al., Cancer Res. 54:3124-3126, 1994)), and 938 with TIL1413 (Kang et al., J. Immunol. 155:1343-1348, 1995). G47 Δ -infected 1102 melanoma cells, with the highest level of MHC class I expression, caused a better stimulation of TIL cells compared to G207-infected cells, resulting in 41% more IFN- γ secretion (Fig. 6). There was essentially no stimulation of this same TIL line with G47 Δ or G207-infected 888 melanoma cells, which had very low levels of MHC class I expression. G47 Δ -infected 938 melanoma cells stimulated TIL1413 cells, causing an increase in IFN- γ secretion that was not statistically significant. The results demonstrate that the higher MHC class I expression that may ensue in G47 Δ versus G207-infected cells can enhance T cell stimulation.

30 Antitumor Efficacy of G47 Δ *In Vivo*

In a human xenograft model, athymic mice harboring established subcutaneous U87MG glioma tumors (approximately 6 mm in diameter), intraneoplastic inoculation of

G207 or G47Δ (10^6 pfu) followed by a second inoculation 3 days later caused a significant reduction in U87MG tumor growth ($p < 0.05$ and $p < 0.001$ versus control on day 24, respectively; unpaired t test; Fig. 7). G47Δ treatment was significantly more efficacious than G207, resulting in reduced average tumor volumes (Fig. 7). This was reflected in the prolonged survival of animals and number of 'cures' (complete tumor regression with no tumor regrowth during a 3-month follow up) (Table 1). At the dose tested, survival was significantly prolonged in the G207-treatment group ($p < 0.05$ versus mock, Wilcoxon test), and to an even greater extent in the G47Δ-treated animals ($p < 0.05$ versus G207, Wilcoxon test).

Table 1. Subcutaneous tumor therapy by G47Δ

Tumor (Mouse)	Number cured/ total treated		
	Mock	G207	G47Δ
U87MG (Athymic)	0/13	3/12	8/12*†
Neuro2a (A/J)	0/10	1/10	3/10

* $p < 0.05$ versus G207, † $p < 0.001$ versus Mock, Fisher's test.

The efficacy of G47Δ was further tested in an immunocompetent mouse tumor model, subcutaneous, poorly immunogenic Neuro2a neuroblastoma tumors in syngeneic A/J mice. Established tumors of approximately 6 mm in diameter were inoculated with mock, G207, or G47Δ (10^6 pfu) on days 0 and 3. Again, while both G207 and G47Δ caused a significant reduction in Neuro2a tumor growth ($p < 0.05$ and $p < 0.001$ versus control on day 15, respectively; unpaired t test), the efficacy of G47Δ was greater than that of G207 (Fig. 7). Kaplan-Meier analysis demonstrated that G207 at this dose did not significantly extend the survival of Neuro2a tumor-bearing A/J mice, whereas G47Δ significantly prolonged survival of the animals compared with mock and G207 ($p < 0.01$ and $p < 0.05$, respectively, Wilcoxon test). In a 3.5-month follow-up period, there was an increased number of 'cures' among the G47Δ-treated mice (not statistically significant, Fisher's test; Table 1).

Safety of G47Δ with intracerebral inoculation

To evaluate the toxicity of G47Δ in the brain, A/J mice were inoculated intracerebrally with mock, strain F (2×10^3 pfu), G207 (2×10^6 pfu), or G47 (2×10^6 pfu). This dose was the highest dose obtainable for G207 in the volume injected. Each mouse was monitored daily for clinical manifestations for 3 weeks. All 8 mock-inoculated mice survived without any abnormal manifestations, whereas all 10 strain F-inoculated mice deteriorated rapidly and became moribund within 7 days of inoculation. All 8 G207-inoculated mice and 10 G47Δ-inoculated mice survived. Two of the G207-inoculated mice and 1 G47Δ-inoculated mouse temporarily manifested (3-6 days post-inoculation) slight hunching or a slightly sluggish response to external stimuli. This shows that G47Δ is as safe as G207 when inoculated in the brain of A/J mice at this dose.

The results described above were obtained using the following Materials and Methods.

Materials and Methods

Cells

Vero (African green monkey kidney), SK-N-SH (human neuroblastoma), U87MG (human glioma), U373MG (human glioma), Neuro2a (murine neuroblastoma), and Detroit 551 (diploid human fibroblast) cell lines were purchased from American Type Culture Collection (Rockville, MD). SQ20B (head and neck squamous cell carcinoma) cells were provided by Dr. R. Weichselbaum (University of Chicago, Chicago, IL). N18 murine neuroblastoma cells were provided by Dr. K. Ikeda (Tokyo Institute of Psychiatry, Tokyo, Japan). Human melanoma cell lines 624, 888, 938, 1102, and 1383, and human T cell lines TIL888 and TIL1413, were provided by Dr. J. Wunderlich (NIH, Bethesda, MD). All tumor cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml), and 2.5 µg/ml Fungizone. Human T cells were maintained in AIM-V medium (Gibco BRL, Life Technologies, Rockville, MD) supplemented with 10% human serum (type AB, Rh⁺; Valley Biomedical Products, Winchester, VA), interleukin 2 (600 international units (IU)/ml, Chiron Corporation, Emeryville, CA), penicillin (50 U/ml), and 1.25 µg/ml Fungizone.

Generation of G47 Δ

Plasmid pIE12 contains an 1818 basepair BamHI-EcoRI fragment from the HSV-1 BamHI x fragment, which encompasses the ICP47 coding region (Johnson et al., J. Virol. 68:6347-6362, 1994). A 312 basepair fragment containing the ICP47 coding region between the BstEII and EcoNI sites was deleted from pIE12 to create pIE12 Δ (Fig. 2C). Vero cells were seeded on 6-well dishes at a density of $1-2 \times 10^5$ cells per well. Transfections were performed using a range of DNA concentrations from 1 to 3 μ g, including a 1:1:1 mixture of G207 DNA (Mineta et al., Nat. Med. 1:938-943, 1995), pIE12 (intact), and pIE12 Δ cleaved with BamHI and XhoI, with 8 μ l LipofectAMINETM (Life Technologies), according to the manufacturer's instructions. The viral progeny from the transfection were then passaged twice in SK-N-SH cells to enrich for recombinants that contained a deletion in ICP47 as follows. SK-N-SH cells were seeded at a density of 5×10^6 cells per 10 cm dish, infected the following day at a range of MOI's from 0.01 to 1 pfu per cell, and harvested at 48 hours post-infection. This process was then repeated. The deletion in pIE12 Δ was designed to generate a second-site suppressor mutation of $\gamma 34.5$ in the virus, and thus permit growth of successful recombinants on SK-N-SH cells (Mohr et al., EMBO J. 15:4759-4766, 1996). Individual plaques from SK-N-SH-enriched stocks were plaque-purified on Vero cells under agarose overlays and screened for the presence of the deletion in ICP47 by Southern blotting. A stock was prepared from one individual plaque that was homogeneous for the ICP47 deletion and designated as G47 Δ . R47 Δ was constructed similarly, except R3616 (Chou et al., Science 250:1262-1266, 1990) DNA was used in place of G207 DNA (R3616 was provided by Dr. B. Roizman, University of Chicago, Chicago, IL). Virus titration was performed as previously described (Miyatake et al., J. Virol. 71:5124-5132, 1997).

Virus Yield Studies

Cells were seeded on 6-well plates at 5×10^5 , 8×10^5 , or 1.6×10^6 cells per well. Triplicate or duplicate wells were infected with the viruses 6-8 hours after seeding at a MOI of 0.01. At 24 or 48 hours post-infection, the cells were scraped into the medium and lysed by three cycles of freeze-thawing. The progeny virus was titered as previously described with a modification (Miyatake et al., J. Virol. 71:5124-5132, 1997). Briefly, Vero cells were plated in 6-well plates at 8×10^5 cells/well. After 4-8 hours incubation

at 37°C, cells were infected in 1 ml growth medium at 37°C overnight, after which 1 ml medium containing 0.4% human IgG (ICN Pharmaceuticals) was added. Wells were incubated at 37°C for another 2 days, and the number of plaques was counted after staining with methylene blue (0.5% w/v in 70% methanol).

5

***In Vitro* Cytotoxicity Studies**

In vitro cytotoxicity studies were performed as previously described (Todo et al., Hum. Gene Ther. 10:2741-2755, 1999), with a modification for human melanoma cells, which were grown in medium containing 10% FCS. The number of surviving cells was counted daily with a Coulter counter (Beckman Coulter, Fullerton, CA) and expressed as a percentage of mock-infected controls.

10

Flow Cytometric Analyses

Cells were plated in 6 well plates at 1×10^6 cells/well and infected with virus (MOI = 3) 24 hours after seeding. Cells were incubated in the presence of ganciclovir (200 ng/ml) at 39.5°C for 6, 24, or 48 hours, harvested by trypsinization, and washed once with 2 ml PBS. G207 and G47Δ contain temperature-sensitive mutations in ICP4, so they can replicate at 37°C, but not at 39.5°C (Mineta et al., Nat. Med. 1:938-943, 1995). Approximately 5×10^5 cells were then used for flow cytometric analyses using FITC-conjugated anti-human HLA class I antigen (clone W6/32, Sigma, St. Louis, MO) and performed as previously described.

20

Human T Cell Stimulation Assays

Human melanoma cells (888, 938, or 1102) were plated in 6 well plates at 5×10^5 cells/well, and infected with G207 or G47Δ (MOI = 3), or without virus (mock) 24 hours after seeding. Cells were incubated in growth medium containing 10% FCS and ganciclovir (200 ng/ml) at 39.5°C for 3 hours (888) or 6 hours (938 and 1102). Cells were then harvested by scraping, and a portion was used for cell counting. Infected melanoma cells (1×10^5) were then co-cultured with an equal number of responding human T cells in 200 μl AIM-V medium containing ganciclovir (200 ng/ml) in a flat-bottom 96-well plate. Melanomas 888 and 1102 were co-cultured with TIL888 cells, and melanoma 938 was cultured with TIL1413 cells. TIL lines 888 and 1413 both recognize tyrosinase, a melanoma antigen, in an HLA-A24 restricted fashion (Robbins et

30

al., Cancer Res. 54:3124-3126, 1994; Kang et al., J. Immunol. 155:1343-1348, 1995). After an 18 hour incubation at 37°C, the plate was centrifuged at 800 g for 10 minutes, and conditioned medium was collected. IFN- γ concentrations were measured by enzyme-linked immunosorbent assay using a human IFN- γ ELISA kit (Endogen, Woburn, MA). The IFN- γ measurements in TIL cells without stimulator cells were considered the base release levels and used to calculate the increase of IFN- γ secretion in stimulated TIL cells.

10 Animal Studies

Six-week-old female A/J mice and athymic nude mice (BALB/c *nu/nu*) were purchased from the National Cancer Institute (Frederick, MD), and caged in groups of four or less. Subcutaneous tumor therapy was performed as previously described (Todo et al., Hum. Gene Ther. 10:2741-2755, 1999; Todo et al., Cancer Res. 61:153-161, 2001).

Intracerebral Inoculation Toxicity Studies

Mock (PBS containing 10% glycerol), strain F (2×10^3 pfu), G207 (2×10^6 pfu), or G47 Δ (2×10^6 pfu) in a volume of 5 μ l was injected over 5 minutes into the right hemisphere of the brains of 6-week-old female A/J mice (n=8, 10, 8, and 10, respectively) using a KOPF stereotactic frame. Cages were then blinded and mice monitored daily for clinical manifestations for 3 weeks.

All references cited herein are incorporated by reference in their entirety. Other embodiments are within the following claims.

25 What is claimed is:

1. A herpes simplex virus comprising a mutation within the BstEII - EcoNI fragment of the BamHI x fragment of said virus.

2. The virus of claim 1, further comprising an inactivating mutation in the γ 34.5 neurovirulence locus of said virus.

3. The virus of claim 1, further comprising an inactivating mutation in the γ 34.5 neurovirulence locus of said virus and an inactivating mutation in the ICP6 locus of said virus.

10

4. A herpes simplex virus comprising an inactivating mutation in the ICP47 locus of said virus, in the absence of an inactivating mutation in the γ 34.5 neurovirulence locus of said virus.

5. The virus of claim 1 or 4, further comprising an inactivating mutation in the ICP6 locus of said virus.

6. A method of inducing a systemic immune response to cancer in a patient, said method comprising administering to said patient a herpes virus comprising an inactivating mutation in the ICP47 locus of said herpes virus.

20

7. The method of claim 6, wherein said herpes virus is administered to a tumor of said patient.

8. The method of claim 6, wherein said patient has or is at risk of developing metastatic cancer.

25

9. The method of claim 6, wherein said inactivating mutation in the ICP47 locus of said herpes virus is in the BstEII - EcoNI fragment of the BamHI x fragment of said virus.

30

10. The method of claim 6, wherein said herpes virus further comprises an inactivating mutation in the γ 34.5 neurovirulence locus of said herpes virus.

11. The method of claim 6, wherein said herpes virus further comprises an inactivating mutation in the ICP6 locus of said herpes virus.

5 12. The method of claim 6, wherein said herpes virus further comprises an inactivating mutation in the γ 34.5 neurovirulence locus of said herpes virus and an inactivating mutation in the ICP6 locus of said herpes virus.

10 13. A herpes virus comprising a first mutation that inactivates the γ 34.5 neurovirulence locus of said virus and a second mutation that results in early expression of US11, in the absence of an ICP47-inactivating mutation in the BamHI x fragment of said virus.

15 14. The virus of claim 13, wherein said virus comprises a promoter inserted upstream from said US11 gene, resulting in said early expression.

 15. The virus of claim 13, wherein said virus comprises a US11 gene under the control of an early-expressing promoter inserted into the genome of said virus.

20 16. The virus of claim 13, wherein said virus comprises a mutation that results in downregulation of ICP47 expression, in the absence of a mutation in the BamHI x fragment of said vector.

25 17. The virus of claim 16, wherein said downregulation of ICP47 expression is due to a deletion in, or inactivation of, the ICP47 promoter.

 18. The virus of claim 16, wherein said virus encodes ICP47 that is fused with a peptide that prevents functional expression of ICP47.

30 19. A herpes virus comprising a first mutation that inactivates the γ 34.5 neurovirulence locus of said virus and a second mutation that results in downregulation of ICP47 expression, in the absence of a mutation in the BamHI x fragment of said virus.

20. The virus of claim 19, wherein said downregulation of ICP47 expression is due to a deletion in, or inactivation of, the ICP47 promoter.

5 21. The virus of claim 19, wherein said virus encodes ICP47 that is fused with a peptide that prevents functional expression of ICP47.

22. The virus of claim 13 or 19, further comprising an additional mutation to prevent reversion to wild type.

10 23. The virus of claim 22, wherein said additional mutation is in the ICP6 locus.

24. The virus of claim 1, 4, 13, or 19, further comprising sequences encoding a heterologous gene product.

15 25. The virus of claim 24, wherein said heterologous gene product comprises a vaccine antigen or an immunomodulatory protein.

26. The virus of claim 13 or 19, wherein said virus is a herpes simplex virus.

20 27. The virus of claim 1, 4, or 26, wherein said herpes simplex virus is a herpes simplex-1 virus.

28. A pharmaceutical composition comprising the virus of claim 1, 4, 13, or 19 and a pharmaceutically acceptable carrier, adjuvant, or diluent.

25

29. A method of treating cancer in a patient, said method comprising administering the pharmaceutical composition of claim 28 to said patient.

30 30. A method of immunizing a patient against an infectious disease, cancer, or an autoimmune disease, said method comprising administering the pharmaceutical composition of claim 28 to said patient.

1/9

FIG. 1A




FIG. 1B





FIG. 1C



2/9

FIG. 1D




FIG. 1E




FIG. 2A




FIG. 2B





FIG. 2C



4/9

FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6





FIG. 7



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09512

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 63/00; A61K 39/12, 39/245; C12N 7/00, 7/04

US CL : 424/93.2, 205.1, 231.1; 435/235.1, 236

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.2, 205.1, 231.1; 435/235.1, 236

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, USPATFULL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,248,320 B1 (COFFIN et al) 19 June 2001(19.06.01), see entire document.	1-26, and 28-30
Y	US 6,261,552 B1 (DeLuca) 17 July 2001(17.07.01), see entire document.	1-26, and 28-30



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 JUNE 2002

Date of mailing of the international search report

03 JUL 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURIE SCHEINER

Telephone No.

(703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09512

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.